XORTX completes gout trial supply; Health Canada and FDA filings are next
Finished clinical supply for the XRX-OXY-102 oxypurinol study removes one common bottleneck, but the record leaves open the filing timing, trial design and funding.
What happened
XORTX Therapeutics says manufacturing and packaging of the drug supply for its oxypurinol tablet gout study, XRX-OXY-102, is finished. The company describes the work as completed ahead of planned filings with Health Canada and the FDA. The product is referred to as XORLO.
The disclosure comes from a company exhibit filed with the SEC. The record does not say when the filings will be made or what type they will be. It also gives no batch size, no manufacturing site, no enrolment target and no trial start date.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- XORTX completes clinical supply manufacturing for XORLO oxypurinol gout trial XRX-OXY-102 XORTX Therapeutics Inc. · Mon 16 Nov 2026
- Bluejay completes SYMON-II enrolment for Symphony IL-6 sepsis test, eyes 510(k) filing in H1 2027 Bluejay Diagnostics, Inc. · Fri 13 Nov 2026
- Boston Scientific updates Vercise DBS Clinician Programmer instructions on battery recharge and longevity estimates Health Canada · Fri 13 Nov 2026
- TuHURA wins FDA IND clearance for VISTA antibody TBS-2025 in relapsed AML TuHURA Biosciences, Inc./NV · Fri 13 Nov 2026
- Oncolytics and Coherus agree toripalimab supply for pelareorep anal cancer study Oncolytics Biotech Inc · Thu 12 Nov 2026
- Slovakia's ŠÚKL issues guideline on notifying intent to vaccinate in pharmacies ŠÚKL · Thu 12 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.